These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 33460074)

  • 1. Commentary on: Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions.
    Czuczwar SJ
    Epilepsia; 2020 Oct; 61(10):2063-2064. PubMed ID: 33460074
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug-drug interactions and pharmacodynamics of concomitant clobazam and cannabidiol or stiripentol in refractory seizures.
    Klein P; Tolbert D; Gidal BE
    Epilepsy Behav; 2019 Oct; 99():106459. PubMed ID: 31519475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trial simulations of the interaction between cannabidiol and clobazam and effect on drop-seizure frequency.
    Bergmann KR; Broekhuizen K; Groeneveld GJ
    Br J Clin Pharmacol; 2020 Feb; 86(2):380-385. PubMed ID: 31657863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials.
    Gunning B; Mazurkiewicz-Bełdzińska M; Chin RFM; Bhathal H; Nortvedt C; Dunayevich E; Checketts D
    Acta Neurol Scand; 2021 Feb; 143(2):154-163. PubMed ID: 32969022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of cannabidiol with other antiseizure medications: A narrative review.
    Gilmartin CGS; Dowd Z; Parker APJ; Harijan P
    Seizure; 2021 Mar; 86():189-196. PubMed ID: 33541771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical implications of trials investigating drug-drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs.
    Patsalos PN; Szaflarski JP; Gidal B; VanLandingham K; Critchley D; Morrison G
    Epilepsia; 2020 Sep; 61(9):1854-1868. PubMed ID: 32918835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions.
    Anderson LL; Absalom NL; Abelev SV; Low IK; Doohan PT; Martin LJ; Chebib M; McGregor IS; Arnold JC
    Epilepsia; 2019 Nov; 60(11):2224-2234. PubMed ID: 31625159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial.
    Thiele EA; Marsh ED; French JA; Mazurkiewicz-Beldzinska M; Benbadis SR; Joshi C; Lyons PD; Taylor A; Roberts C; Sommerville K;
    Lancet; 2018 Mar; 391(10125):1085-1096. PubMed ID: 29395273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of antiseizure medication for Lennox-Gastaut syndrome: a systematic review and network meta-analysis.
    Zhang L; Wang J; Wang C
    Dev Med Child Neurol; 2022 Mar; 64(3):305-313. PubMed ID: 34590711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cannabidiol as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.
    Lattanzi S; Trinka E; Russo E; Striano P; Citraro R; Silvestrini M; Brigo F
    Drugs Today (Barc); 2019 Mar; 55(3):177-196. PubMed ID: 30938373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cannabidiol: A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes.
    Chen JW; Borgelt LM; Blackmer AB
    Ann Pharmacother; 2019 Jun; 53(6):603-611. PubMed ID: 30616356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lennox-Gastaut syndrome: New treatments and treatments under investigation.
    Auvin S
    Rev Neurol (Paris); 2020 Jun; 176(6):444-447. PubMed ID: 32409177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cannabidiol for epilepsy: trying to see through the haze.
    Detyniecki K; Hirsch LJ
    Lancet Neurol; 2016 Mar; 15(3):235-7. PubMed ID: 26776916
    [No Abstract]   [Full Text] [Related]  

  • 14. Cannabis for the Treatment of Epilepsy: an Update.
    Gaston TE; Szaflarski JP
    Curr Neurol Neurosci Rep; 2018 Sep; 18(11):73. PubMed ID: 30194563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse effects of cannabinoids.
    Anciones C; Gil-Nagel A
    Epileptic Disord; 2020 Jan; 22(S1):29-32. PubMed ID: 31941644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel therapeutic options for Dravet and Lennox-Gastaut syndrome.
    Verrotti A; Striano P
    Expert Rev Neurother; 2021 Nov; 21(11):1191-1194. PubMed ID: 33297778
    [No Abstract]   [Full Text] [Related]  

  • 17. Clobazam and Aggression-Related Adverse Events in Pediatric Patients With Lennox-Gastaut Syndrome.
    Paolicchi JM; Ross G; Lee D; Drummond R; Isojarvi J
    Pediatr Neurol; 2015 Oct; 53(4):338-42. PubMed ID: 26245776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacology and drug interactions of cannabinoids.
    Landmark CJ; Brandl U
    Epileptic Disord; 2020 Jan; 22(S1):16-22. PubMed ID: 31941642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the Effects of Clobazam on Seizure Control and Quality of Life in Children With Lennox-Gastaut Syndrome: A Pilot Study.
    Weinstock A; Agarwal N; Farooq O; Cheema Z; Hamilton D; Parrish J
    J Child Neurol; 2019 Jul; 34(8):432-439. PubMed ID: 30913948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comment on "Cost-Effectiveness of Cannabidiol Adjunct Therapy Versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome".
    Hollenack K; Marshall J
    Pharmacoeconomics; 2021 Apr; 39(4):473-475. PubMed ID: 33674999
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.